Search research articles
Contact Us
Filters
Showing results (1-10 of 179) with videos related to
Page
of 18
Sort By:
Proceedings of the National Academy of Sciences of the United States of America
|
March 18, 2020
A vital gene for modified vaccinia virus Ankara replication in human cells
Gerd Sutter
Current Opinion in Virology
|
June 18, 2017
Editorial overview: Preventive and therapeutic vaccines: Vaccination against viral disease - current advances and challenges
Rino Rappuoli, Gerd Sutter
Vaccine
|
March 26, 2013
Protective efficacy of Modified Vaccinia virus Ankara in preclinical studies
Asisa Volz, Gerd Sutter
Methods in Molecular Medicine
|
September 6, 2003
Live viral vectors: vaccinia virus
Caroline Staib, Gerd Sutter
Current Drug Targets. Infectious Disorders
|
October 8, 2003
Vaccinia vectors as candidate vaccines: the development of modified vaccinia virus Ankara for antigen delivery
Gerd Sutter, Caroline Staib
Human Vaccines
|
December 1, 2009
Smallpox vaccines: New formulations and revised strategies for vaccination
Nir Paran, Gerd Sutter
Clinical and Vaccine Immunology : CVI
|
April 30, 2015
Use of the LC16m8 Smallpox Vaccine in Immunocompromised Individuals Is Still Too Risky
Yehuda L Danon, Gerd Sutter
Expert Review of Vaccines
|
April 8, 2009
Candidate influenza vaccines based on recombinant modified vaccinia virus Ankara
Guus F Rimmelzwaan, Gerd Sutter
Frontiers in Immunology
|
August 28, 2020
Combating COVID-19: MVA Vector Vaccines Applied to the Respiratory Tract as Promising Approach Toward Protective Immunity in the Lung
Reinhold Förster, Henrike Fleige, Gerd Sutter
Current Opinion in Biotechnology
|
November 25, 2004
Modified vaccinia virus Ankara as antigen delivery system: how can we best use its potential?
Ingo Drexler, Caroline Staib, Gerd Sutter
Page
of 18
Search research articles
Search
Showing results (1-10 of 179) with videos related to
Sort By:
Page
of 18
Proceedings of the National Academy of Sciences of the United States of America
|
March 18, 2020
A vital gene for modified vaccinia virus Ankara replication in human cells
Gerd Sutter
Current Opinion in Virology
|
June 18, 2017
Editorial overview: Preventive and therapeutic vaccines: Vaccination against viral disease - current advances and challenges
Rino Rappuoli, Gerd Sutter
Vaccine
|
March 26, 2013
Protective efficacy of Modified Vaccinia virus Ankara in preclinical studies
Asisa Volz, Gerd Sutter
Methods in Molecular Medicine
|
September 6, 2003
Live viral vectors: vaccinia virus
Caroline Staib, Gerd Sutter
Current Drug Targets. Infectious Disorders
|
October 8, 2003
Vaccinia vectors as candidate vaccines: the development of modified vaccinia virus Ankara for antigen delivery
Gerd Sutter, Caroline Staib
Human Vaccines
|
December 1, 2009
Smallpox vaccines: New formulations and revised strategies for vaccination
Nir Paran, Gerd Sutter
Clinical and Vaccine Immunology : CVI
|
April 30, 2015
Use of the LC16m8 Smallpox Vaccine in Immunocompromised Individuals Is Still Too Risky
Yehuda L Danon, Gerd Sutter
Expert Review of Vaccines
|
April 8, 2009
Candidate influenza vaccines based on recombinant modified vaccinia virus Ankara
Guus F Rimmelzwaan, Gerd Sutter
Frontiers in Immunology
|
August 28, 2020
Combating COVID-19: MVA Vector Vaccines Applied to the Respiratory Tract as Promising Approach Toward Protective Immunity in the Lung
Reinhold Förster, Henrike Fleige, Gerd Sutter
Current Opinion in Biotechnology
|
November 25, 2004
Modified vaccinia virus Ankara as antigen delivery system: how can we best use its potential?
Ingo Drexler, Caroline Staib, Gerd Sutter
Page
of 18